A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …Read More
Each year, the American Association for Cancer Research (AACR) is proud to bring Associate Members to Washington, D.C., where they meet with legislators and policymakers to discuss issues that are critical to supporting medical research.Read More
A study presented in the AACR Annual Meeting 2018 Media Preview webinar, held March 15, examined closely a key ingredient necessary to make effective chimeric antigen receptor (CAR) T cells – the T cells of a patient. The researchers behind this study have identified one potential reason for why we have not been successful in making CAR T-cell therapy work against solid tumors, and offer a solution.Read More
In less than a month, the AACR Annual Meeting 2018 will kick off in Chicago, Illinois. The meeting is expected to draw about 22,000 attendees, including cancer researchers, clinicians, and advocates.
As always, the meeting features a wide range of high-impact science, featuring presentations on all aspects of basic and translational cancer research, including immunotherapy, precision medicine, artificial intelligence, liquid biopsy, early detection, cancer interception, prevention, cancer disparities, and survivorship.Read More
A recent blog post by the Sidney Kimmel Cancer Center – Jefferson Health examined whether the power of immunotherapy can be used to treat pancreatic cancer. The blog featured a …Read More
Editor’s note: February is Cancer Prevention Month. That’s why the American Association for Cancer Research (AACR) has been pleased to support the American Institute for Cancer Research (AICR) Cancer Prevention: Together We Can campaign, an initiative dedicated to promoting evidence-based information to reduce cancer risk. This blog post was developed and shared by the AICR.Read More
Cigarette smoking is linked to 18 different types of cancer. It is the leading preventable cause of cancer in the United States, accounting for 19 percent of the 1,570,978 cancers diagnosed in U.S. adults ages 30 and older in 2014, according to the latest research. Another 0.4 percent of the cancer diagnoses in the U.S. that year were attributable to exposure to secondhand smoke.
That’s why February, which is National Cancer Prevention Month, is a good time to raise awareness of the dangers of cigarette smoking and exposure to secondhand smoke.Read More
Together with the Radiation Research Society, the AACR will present a workshop titled Targeting Cancer Metabolism to Improve Radiotherapy from February 28 – March 2 in Big Sky, Montana.Read More
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include the treatment of certain patients with the most common form of lung cancer—non–small cell lung cancer (NSCLC).Read More
Last week, the U.S. Food and Drug Administration (FDA) approved the antihormone agent apalutamide (Erleada) for treating men with nonmetastatic prostate cancer that has stopped responding to standard antihormone treatments.Read More
The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as multiple myeloma and metastatic melanoma, are turning into chronic diseases due to the use of novel, targeted systemic therapies. Immunotherapy is altering the natural history of certain malignancies.Read More